Matthew Coates

Featured in: Favicon

bmj.com (+1) Favicon

jamanetwork.com Favicon

deseret.com Favicon

thelancet.com Favicon

archinect.com Favicon

ersjournals.com Favicon

mondaq.com Favicon

biorxiv.org Favicon

erj.ersjournals.com

Articles

Study protocol for a randomised, phase II, double-blind, experimental medicine study of obinutuzumab versus rituximab in ANCA-associated vasculitis: ObiVas

Jul 18, 2024 | bmjopen.bmj.com | Dominic McGovern |Mark McClure |Matthew Coates |Simon Bond

Immunology (including allergy) Study protocol for a randomised, phase II, double-blind, experimental medicine study of obinutuzumab versus rituximab in ANCA-associated vasculitis: ObiVas Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →